Amarin | AMRN - Gewinn Vor Steuern

Aktienkurs
14.48
Täglich Wechseln
-0.30 -2.03%
Monatlich
-11.27%
Jährlich
55.70%
Q2 Prognose
14.06




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
DBV Technologies USD -33.16M 8.6M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12